Expert consensus on the off-label use in China of drugs for rare hematologic diseases (2024 edition)

• Main Authors: Boxin Zhao (Author), Xuan Zhou (Author), Ping Zheng (Author), Bo Zhang (Author), Xiaoqin Feng (Author), Jie Chen (Author), Lisheng Cai (Author), Yilu Chen (Author), Liya He (Author), Jianfen Su (Author), Shuqin Cheng (Author), Yingtong Zeng (Author), Guowei Li (Author), Bo Ji (Author), Jianlong Wu (Author), Weiyi Feng (Author), Maobai Liu (Author), Yiran Jin (Author), Taotao Liu (Author), Xiaolan Mo (Author), Junyan Wu (Author), Hui Wu (Author), Hongliang Zhang (Author), Zhichang Zheng (Author), Zhihua Zheng (Author), Jing Sun (Author), Yilei Li (Author), Guangdong Pharmaceutical Association, Hematology Group of Rare Disease Expert Committee of Guangdong Pharmaceutical Association (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Drug package inserts are a crucial foundation for clinical medication practices and serve as the legal basis for guiding rational drug use and ensuring patient safety and efficacy. As rare disease treatments evolve, current package inserts often need to meet the clinical requirements for treating su...